Chemistry:Telapristone

Short description: Chemical compound

Telapristone

Clinical data
Other names	CDB-4124; Proellex; Progenta; 17β-(Acetyloxy)-11β-[4-(dimethylamino)phenyl]-17α-(2-methoxyacetyl)estra-4,9-dien-3-one
Drug class	Selective progesterone receptor modulator
Legal status
Legal status	Investigational
Identifiers
IUPAC name [(8S,11R,13S,14S,17R)-11-[4-(Dimethylamino)phenyl]-17-(2-methoxyacetyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
CAS Number	198414-31-2
PubChem CID	9806190
PubChem SID	347910049
DrugBank	DB05253 Y
ChemSpider	7981950 Y
UNII	1K9EYK92PQ
ChEMBL	ChEMBL2105694
Chemical and physical data
Formula	C31H39NO5
Molar mass	505.655 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C5\C=C3/C(=C2/[C@@H](c1ccc(N(C)C)cc1)C[C@@]4([C@@](OC(=O)C)(C(=O)COC)CC[C@H]4[C@@H]2CC3)C)CC5
InChI InChI=1S/C31H39NO5/c1-19(33)37-31(28(35)18-36-5)15-14-27-25-12-8-21-16-23(34)11-13-24(21)29(25)26(17-30(27,31)2)20-6-9-22(10-7-20)32(3)4/h6-7,9-10,16,25-27H,8,11-15,17-18H2,1-5H3/t25-,26+,27-,30-,31-/m0/s1 Y Key:JVBGZFRPTRKSBB-MJBQOYBXSA-N Y
(verify)

Telapristone (INN), as telapristone acetate (proposed brand names Proellex, Progenta; former code name CDB-4124), is a synthetic, steroidal selective progesterone receptor modulator (SPRM) related to mifepristone which is under development by Repros Therapeutics for the treatment of breast cancer, endometriosis, and uterine fibroids. It was originally developed by the National Institutes of Health (NIH), and, as of 2017, is in phase II clinical trials for the aforementioned indications. In addition to its activity as an SPRM, the drug also has some antiglucocorticoid activity.

See also

• List of investigational sex-hormonal agents § Progestogenics
• Aglepristone
• Lilopristone
• Onapristone
• Toripristone

External links

• Telapristone - AdisInsight